March 24, 2015

Actavis last week announced that its acquisition of Allergan has been completed in a transaction valued at $70.5 billion, a deal that creates one of the world’s top 10 pharmaceutical companies by sales revenue, according to the company.

February 24, 2015

Lupin will bring to market a generic version of Lumigan solution, the company announced. 

February 18, 2015

Actavis on Wednesday announced that it will adopt a new corporate name — Allergan — following the anticipated, successful completion of the acquisition of Allergan.

January 27, 2015

Actavis on Monday agreed to acquire Auden Mckenzie Holdings for approximately $465.8 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products.

December 23, 2014

Specialty pharmaceutical company Actavis has hired Jonathon Kellerman as EVP, global chief compliance officer.

December 16, 2014

Actavis on Tuesday announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan.

November 17, 2014

Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock, the company announced Monday.

August 19, 2014

Nearly half of women age 45 years or older who experience symptoms of overactive bladder report their current treatment does not address their OAB symptoms, according to a recent survey conducted by The Harris Poll on behalf of Allergan.

July 25, 2014

In an effort to show investors that its able to deliver strong earnings growth, drug maker Allergan will be laying off workers and discontinuing some of its drug research, according to the Wall Street Journal.

July 15, 2014

John Biles, who led the University of Southern California’s School of Pharmacy for 27 years, died June 27.

 

June 16, 2014

Allergan issued a statement Monday, reiterating the company's concern for what it calls Valeant Pharmaceuticals’ “unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operational excellence,” the company stated.

April 22, 2014

Allergan on Tuesday confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals to acquire all of the outstanding shares of the company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of Allergan.

October 8, 2013

Lupin Pharmaceuticals announced today that it has launched its generic gatifloxacin ophthalmic solution 0.5%. Lupin had earlier received final approval from the Food and Drug Administration to market a generic version of Allergan's Zymaxid ophthalmic solution, 0.5%, which is indicated for the treatment of bacterial conjunctivitis.

September 16, 2013

The McKesson Patient Relationship Solutions was recognized for its best-in-class adherence solutions by being named a finalist in the 2013 PM360 Trailblazer Awards for the second consecutive year.

June 25, 2013

Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

September 7, 2012

McKesson Patient Relationship Solutions has been named a finalist in both the 2012 Medical Marketing and Media Awards and the PM360 Trailblazer Awards, McKesson announced Friday.

June 19, 2012

The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

April 4, 2012

A court has ruled that patents covering a drug used for overactive bladder are invalid, a company looking to launch a generic version of the drug said.

April 3, 2012

Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

May 9, 2011

Cypress Pharmaceuticals has launched a generic version of an eye care drug made by Boehringer Ingelheim and marketed by Allergan, the company said.

March 9, 2011

Allergan reappointed David Pyott as president earlier this week, adding to his role as chairman and CEO. Pyott will succeed Michael Ball, who has accepted the position of CEO at Hospira, a specialty pharmaceutical and medication delivery company, Allergan reported.

March 8, 2011

Generic drug maker Hospira has appointed Mike Ball as CEO, effective March 28, the company said. Ball currently is president of Allergan.

February 8, 2011

Valeant Pharmaceuticals subsidiary Biovail Labs International has licensed Canadian rights to a treatment for acne from Allergan, Valeant said Tuesday.

February 1, 2011

Thanks to technological innovations within mascara, the category has driven sales of eye makeup, and looking forward, mascara formulas that are infused with eyelash-enhancing treatments and packaging that offers greater customization not only will volumize lashes but also sales at retail.